Accordingly, the aim of this preliminary study was to evaluate the serum levels of uPA, PAI-1, and suPAR and determine their clinical correlations with the fibrotic and vascular complications that occur in patients with SSc. This evidence concerns the gene PLAU and systemic sclerosis.